Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The telmisartan market was valued at USD 3.77 Billion in 2025 driven by rising prevalence of hypertension and cardiovascular diseases across the 8 major markets. It is expected to grow at a CAGR of 5.60% during the forecast period 2026-2035 and attain a market value of USD 6.50 Billion by 2035.
Base Year
Historical Period
Forecast Period
The rising prevalence of hypertension and the growing aging population are expected to drive market growth in the forecast period.
Combining Telmisartan with other antihypertensive agents is a major market trend. For instance, in May 2024, Akums introduced a new FDC medication, Amlodipine, Telmisartan & Metoprolol (ER) film-coated tablets for resistant hypertension, approved by DCGI.
The robust regulatory support from health authorities like the FDA is likely to elevate the market value.
Compound Annual Growth Rate
5.6%
Value in USD Billion
2026-2035
*this image is indicative*
Telmisartan is a medication utilized for treating high blood pressure and reducing the risk of cardiovascular conditions, particularly in individuals at high risk, which aids in averting issues such as heart attacks, strokes, and kidney complications. The mechanism involves the inhibition of angiotensin II, leading to the dilation of blood vessels, enhancing circulation, and decreasing strain on the heart.
It is additionally utilized for managing heart failure and protecting the kidneys in diabetic patients. Blocking angiotensin II helps lower blood pressure and enhance blood circulation, promoting heart well-being and safeguarding the kidneys. Possible side effects include feeling dizzy, tired, and getting infections, as well as possible reactions with diuretics, NSAIDs, and specific supplements. Unhealthy lifestyle habits like poor diet, smoking, and lack of physical activity are contributing to the growth in hypertension cases, which is anticipated to boost the market demand in the forecast.
Rising Prevalence of Hypertension Spurs Market Growth
Hypertension, a common condition with serious health risks, is rising due to factors such as aging populations and unhealthy lifestyle choices. In 2022 , the CDC reported that high blood pressure was linked to 685,875 deaths in the United States. Further, it is reported that roughly half the adults have high blood pressure. Telmisartan, an effective blood pressure medication, is widely used to manage hypertension by blocking angiotensin II. Rising awareness of hypertension's dangers is leading to earlier diagnosis and treatment, thereby increasing demand for drugs like telmisartan. Additionally, guidelines recommending aggressive blood pressure management are poised to boost the usage of telmisartan in the coming years.
Telmisartan in Fixed-Dose Combinations (FDCs) is Likely to Augment Demand in the Telmisartan Market
Telmisartan's inclusion in Fixed-Dose Combinations (FDCs) with other drugs like diuretics or calcium channel blockers further boosts its market growth. In May 2024, Akums introduced a new FDC medication, Amlodipine, Telmisartan & Metoprolol (ER) film-coated tablets for resistant hypertension, approved by DCGI. It integrates established medications to effectively control blood pressure. FDCs offer improved therapeutic efficacy, simplified treatment regimens, and enhanced patient compliance, ultimately leading to better long-term blood pressure control and reduced healthcare costs. The growing acceptance of FDCs in medical practice is driving demand for telmisartan-based combinations, solidifying its position in the hypertension market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
“Telmisartan Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Dosage
Market Breakup by Administration
Market Breakup by Application
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on the Application to Witness Growth
Based on the application, the market is divided into hypertension, cardiovascular disease, and others. The hypertension application is expected to dominate the market share because of the ability of telmisartan to regulate high blood pressure, a key factor in cardiovascular diseases. Its importance as the initial treatment is vital for patients with conditions such as diabetes or kidney disease. The high demand for telmisartan is also propelled by the elevated occurrence of hypertension, particularly in older populations and areas with lifestyle-related health hazards.
Distribution Channel Segment Holds a Substantial Market Share
Hospital pharmacies, independent pharmacies, online pharmacies, and others are the major distribution channels in the market. Hospital pharmacies are expected to dominate the market due to the large number of prescriptions for high blood pressure and heart conditions coming from hospitals. Hospital pharmacies provide quick access to medications and encourage adherence to treatment plans. Specialized hospital units also guarantee proper administration and monitoring of telmisartan for high-risk groups with complicated medical backgrounds.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.
The United States leads the market share due to the presence of a significant number of older individuals with hypertension and heart problems in the region, who receive assistance from government health programs. Many generic choices are readily accessible, encouraging the use of generic telmisartan medications available at reduced prices.
EU-4 and the United Kingdom are also poised to have a significant market share. Government programs and healthcare systems ensure the availability of telmisartan. Heightened awareness and widespread availability of generic products continue to drive market expansion in the region.
The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Verdant Life Scie nces Pvt Ltd Verdant Life Sciences Pvt. Ltd, established in 2008, is a top telmisartan manufacturer in India due to its commitment to improving research capabilities and prioritizing patients' well-being. With the rise in demand for medical services, the company has made a significant mark in the market for its high-quality, life-saving drugs.
Boehringer Ingelheim International GmbH is a pharmaceutical company under CH Boehringer Sohn AG & Co KG, which is developing, manufacturing, and marketing pharmaceuticals, parasiticides, vaccines, and therapeutics for unmet medical needs such as human diseases, animal health care, and biopharmaceuticals.
Wellona Pharma, a reputable pharmaceutical manufacturing company in Gujarat, India, has been leading in the production, export, and supply of various pharmaceutical formulations such as tablets, capsules, injections, and more for over a decade. The company specializes in the production of Telmisartan and Amlodipine 80 mg Tablets, used for various medical conditions such as hypertension, coronary artery disease, high blood pressure, and others. Wellona Pharma is known for its high-quality products and quick delivery to clients worldwide, making it a top choice among pharmaceutical manufacturers in India.
Glenmark Pharmaceuticals Limited, headquartered in Mumbai, India, is a multinational company focused on improving patient lives globally. They specialize in innovative/specialty, generics, and OTC products in areas like dermatology, respiratory, and oncology, with a strong presence in diabetes, cardiovascular, and oral contraceptives. Glenmark prioritizes research and development to innovate and address patient needs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include CTX Lifesciences Pvt Ltd, Atom Pharma, Cerata Pharmaceuticals, Centurion Healthcare, and Scott Morrison.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Dosage |
|
| Breakup by Administration |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share